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Case presentation
A 58-year-old man was referred to Columbia Presbyterian Medical
Center because a routine prostate-specific antigen (PSA) determination
was elevated at 22.4 ng/ml. An enzymatic essay for prostatic acid
phosphatase was normal (2.5 ng/ml). Of interest was the fact that his
father died at age 62 of prostatic cancer.
The patient had no urinary symptoms. His general physical exami-
nation was unremarkable. Rectal examination revealed a 2 cm nodule in
the left side of the prostate gland. Transrectal needle biopsy of this
nodule revealed a well-differentiated adenocarcinoma of the prostate. A
bone scan was negative for metastatic involvement, a CT scan showed
no evidence of seminal vesicle extension, and there was no evidence of
pelvic lymphadenopathy.
After carefully reviewing his therapeutic options with the attending
urologist, the patient elected radical prostatectomy. This operation was
carried out, along with bilateral pelvic lymph node sampling, without
incident. The pathology specimen revealed a Gleason 6 adenocarci-
noma of the prostate. Inked margins of resection were negative for
tumor involvement. Seminal vesicles were negative for tumor, and no
lymphadenopathy was present.
The patient was discharged on the 7th hospital day and returned to
the office for catheter removal on the 14th postoperative day. He had
immediate excellent urinary control. A serum PSA obtained one month
following surgery was less than 0.4 ng/ml. Four months postopera-
tively, the PSA level was undetectable. At that time, he reported
normal erectile capability and normal sexual function. At his last
followup, 2.5 years postoperatively, rectal examination revealed no
evidence of local recurrence, and the PSA remained undetectable.
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Discussion
DR. CARL OLSSON (Professor and Chairman, Department of
Urology, Columbia-Presbyterian Medical Center, New York,
New York): Adenocarcinoma of the prostate is the most com-
mon form of cancer in the American male and it is the second
most frequent cause of cancer-related death in men in the
United States [1]. The incidence of this disease is rising
remarkably in the United States [1]. In 1987, the number of new
cases in this country was 90,000; this year we will see 132,000
new cases; by 1995 it is likely that 200,000 new cases will occur
[2]. In this discussion I will review the general topic of prostate
cancer, highlighting areas of current controversy.
Patho genesis
The pathogenesis of prostatic cancer remains unknown. The
ras family of oncogenes has been implicated in the etiology of
this disease, however [3]. Indeed, co-transfection of ras and
myc oncogenes in reconstituted fetal cloacal tissue produces
prostatic neoplasms [4]. The HER-2/neu gene was recently
found in 50% of human prostatic cancer tissue studied [5].
Whether these genes are actually causative or whether they
represent coincidental ("passenger") events in carcinogenesis
remains obscure, however. Suppressor genes also might partic-
ipate in prostatic carcinogenesis. Inactivation of the p53 sup-
pressor gene has been implicated in the pathogenesis of pros-
tatic cancer [6]. In another study, so-called retinoblastoma gene
(another suppressor gene) transcripts were absent in one-third
of the prostatic cancer specimens studied [7].
Epidemiologic studies of prostatic cancer point to racial and
geographic differences worthy of further study. The incidence
of prostatic cancer found at autopsy is similar throughout the
world [8]. Yet a significant difference exists in the incidence of
clinical disease. While the clinical disease is extremely rare in
certain Asian countries, nearly all western civilizations experi-
ence a significantly higher disease rate, averaging 60 cases per
100,000 males [9]. Interestingly, when an Asian man moves to
the United States, his risk for prostatic cancer climbs to nearly
half that of the American male; the obvious implication is that
environmental factors likely play a role. The higher incidence of
prostatic cancer in blacks than in whites in the United States, as
well as the more prominent morbidity and mortality of the
disease in blacks, suggests that genetic factors contribute to the
disease as well [10]. An interesting hypothesis has been put
forth recently by Gittes in an attempt to explain a number of
epidemiologic observations [11]. Gittes notes that a high testos-
terone level is associated with an increased risk of prostatic
cancer, observes that vegetarian diets such as those in Asian
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countries can lower serum testosterone levels, and further
observes that black men have testosterone levels 15% higher
than white men. Gittes then theorizes that most of the epide-
miologic data could be explained satisfactorily by differences in
testosterone levels in different male populations [11].
Finally, familial aggregates of prostatic cancer have been
identified [12]. Men who have first- and second-degree relatives
with prostatic cancer have a two- to threefold greater risk of
developing this disease. More recently, segregation analysis of
families with prostatic cancer hypothesized that the best genetic
model for explaining the elevated risk was that of co-dominant
inheritance of a rare major autosomal gene controlling the
susceptibility to prostatic cancer [13].
Detection and diagnosis
Prostatic cancer is diagnosed via histologic analysis of pros-
tatic tissue obtained by biopsy. Current biopsy techniques,
performed transrectally, use one of a number of biopsy needle
guns that can be directed digitally or guided by simultaneous
transrectal ultrasound (TRUS) examination of the prostate
gland [14]. Systematic, random biopsies have been advocated
by others as also enhancing the diagnostic yield [15]. A number
of TRUS probes have special channels that can accommodate
the biopsy needle-gun apparatus, The biopsy can be performed
as an office procedure with no need for anesthesia and minor
preoperative preparation. Typically the patient self-administers
a commercially available enema on the morning of the proce-
dure. A broad-spectrum antibiotic is administered prior to and
for 24 hours after the biopsy, although solid evidence does not
support this approach. Complications of biopsy include bleed-
ing and sepsis, each of which occurs in a very small percentage
of patients [16].
One of the most controversial areas in the field of prostatic
cancer is the determination of a patient's candidacy for trans-
rectal biopsy. Should one screen otherwise-healthy populations
of men for prostatic cancer? How should such screening be
performed? Most urologists believe that thorough digital rectal
examination (DRE) should be performed annually when a man
reaches the age of 50 years [17]. Although no study has yet
indicated that adhering to this practice reduces the mortality
rate from prostatic cancer, this recommendation is, at the least,
a judicious practice. More recently, both TRUS and serum
marker assays have come into vogue as screening tools.
With regard to the latter, prostate-specific antigen (PSA)
testing has become popular as a standard screening tool for
prostatic cancer [181. Measurement of PSA, a protein exclu-
sively produced by prostatic epithelial cells [19], has become
recognized as the most sensitive method for monitoring the
response of prostatic cancer to therapy as well as for following
disease progression [20, 21]. Because PSA is a protein produced
both by benign and malignant tissue, the baseline "normal
level" that serves as "trip point" to warrant biopsy is itself a
controversial matter. A number of assays for PSA are commer-
cially available. The most frequently employed was developed
by the Hybritech Corporation. Most commercial laboratories
utilize this assay, so I will use the Hybritech values in the rest
of this discussion.
Most urologists now agree that a man whose Hybritech PSA
value exceeds 10 nglml should undergo further testing. Hudson
et al, for example, found that only 2% of patients with benign
prostatic enlargement had PSA levels over 10 nglml; in con-
trast, 44% of patients with pro static cancer had high levels [22].
The upper limit of normal utilized in most laboratories is 4 nglml
for the Hybritech PSA determination. The question of how to
manage a patient with so-called intermediate PSA levels, that
is, between 4 nglml and 10 ng/ml, remains debatable. We
recently developed the concept of "PSA density" [231. The
prostatic volume (in cc's) is estimated by TRUS measurement,
and the serum PSA level is divided by this value to yield the
"PSA density" (PSAD, amount of PSA produced per unit
volume of prostate). A nomogram then allows the physician to
derive positive and negative predictive values for the individual
patient. In our analysis of 523 patients, if the PSAD was 0.15
ng/mllcc, the cancer was seen in only 8%; lIthe PSAD was 0.25
ng/mllcc, we found cancer in 20%; and if the PSAD was 0.6
ng/mllcc, 84% developed prostatic cancer.
Another approach, simply following patients with intermedi-
ate levels of PSA elevation, involves monitoring the rise of PSA
over time [24]. Since the amount of PSA produced per gram of
prostatic cancer tissue is higher than that produced by benign
prostatic hypertrophy (BPH) tissue, the slope of the PSA rise is
significantly higher in cancer patients than in those with BPH.
Catalona and coworkers have advocated routine serum PSA
determination as a screening test for prostatic cancer [25].
Before data were available on the slope of the PSA and on PSA
density, Catalona and colleagues conducted a large study in
more than 1650 men who were 50 years of age or older. Those
with PSA values over 4 ng/ml were further studied with DRE
and TRUS. Biopsies were performed when an abnormality was
noted on digital rectal examination transrectal ultrasound. The
serum PSA was above 10 ng/ml in approximately 2% of the men
studied and ranged from 4.0 to 9.9 in more than 6% of the men.
Of those undergoing biopsy, 67% of men with PSA values
higher than 10 ng/ml had cancer; 22% of men with intermediate
PSA levels had cancer. In absolute terms, the numbers of
patients with prostatic cancer were nearly identical in those
with intermediate values and in those with values greater than
10 nglml. As Catalona admitted and others emphasized, the
PSA level alone is insufficient to screen for prostatic cancer.
Normal PSA values occur in 20% to 30% of men with prostatic
cancer [25, 26]. However, the time-honored digital rectal ex-
amination might not be an adequate screen either. In Catalona's
study, 28% of men with a normal digital rectal examination but
abnormalities on PSA and TRUS had cancer on biopsy; of the
combinations of any two screening tests in this study, PSA
measurement along with digital rectal examination had the
lowest error rate [25]. Cooner et al found an even higher
percentage of men—35%-—with a negative DRE and abnormal-
ities on TRUS and PSA who had cancer [27].
Enthusiasts of TRUS studies use these reports to establish
the superiority of TRUS over DRE and to advocate TRUS in
screening for prostatic cancer [28]. But TRUS is not foolproof.
In two studies, TRUS failed to detect as many as 30% of lesions
that were palpable on DRE; in addition, only 20% of the
hypo-echoic nodules discovered by TRUS were really cancer-
ous [29, 301. I might add that the cost of these tests at our
institution is $48 for DRE, $50 for a PSA, and $150 for TRUS.
Thus, no single evaluation technique is a sufficient screening
tool. Some clinicians even deny the value of screening for
prostatic cancer [31]. They believe that screening will detect
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incidental prostate tumors (that is, lesions that are clinically
insignificant—those found only at autopsy), which occur in 30%
of men over the age of 50 years. It is generally agreed that these
cancers do not require therapy. If all were found and removed
surgically, the annual mortality might reach 50,000 assuming an
operative mortality rate of 1%. This number exceeds the
current annual mortality rate from adenocarcinoma of the
prostate. Second, it has been argued that any apparent im-
proved survival accomplished by such early detection simply
results from "lead-time bias."
In many respects, patients' own attitudes play a major role in
determining whether one screens for prostatic cancer. There
are few upper- and middle-class men in the United States who
haven't heard of the serum test for PSA. As a consequence,
many men now insist that their family physicians or internists
obtain PSA measurements during annual physical examina-
tions. I believe that all men with palpable abnormalities on DRE
should undergo prostate biopsy, regardless of the PSA level. If
PSA determinations have been obtained, individuals with PSA
levels above 10 ng/ml should have TRUS and biopsy whether or
not abnormal foci are found. Any individual with a PSA value in
the intermediate range (4—10 ng/ml) whose PSA density exceeds
0.15 also should undergo TRUS with biopsy of abnormal foci.
Staging techniques
Most prostatic cancers arise in the peripheral zone of the
prostate gland and are usually palpable by DRE. Less com-
monly, cancer occurs in the transitional zone, the portion of the
prostate removed during transurethral resection (TUR) of the
gland [32]. Centrifugal growth through the prostate capsule
occurs via perineural spaces that perforate the capsule at the
apex and base [33]. When capsular penetration occurs, common
sites of direct extension include the bladder neck and the
seminal vesicles. Metastases occur predominantly via venous
and lymphatic routes; obturator and hypogastric nodes are most
commonly affected initially [34]. Hematogenous spread to the
axial skeleton is a common route of distant metastasis [35].
Because of this pattern of local extension and metastatic
spread, the staging studies useful in prostatic cancer are those
that indicate or correlate with local extension, lymph node
involvement, and bony spread. Variable results are obtained
when DRE, TRUS, CT imaging, and MRI are used in an
attempt to discover extracapsular extension. Mixed results
occur when CT scans and MR imaging are used to detect pelvic
lymphadenopathy. Radioisotope bone scans remain the main-
stay in the detection of metastases to the axial skeleton [351.
The accuracy of various techniques in judging the extracap-
sular extent of prostatic cancer is variable. The presence of
extracapsular spread is usually thought to be a contraindication
for surgical therapy, and this assessment, if incorrect, could
exclude patients from curative surgery. Unfortunately, all our
current staging techniques carry the possibility of error in
assessing the local extent of the lesion. For example, Ebert and
coworkers found that DRE was correct only 21% of the time,
and that it understaged the tumor extent in 77% of patients [37].
In the same series, CT scan did not perform significantly better:
24% of cases were judged correctly by CT, but 67% were
understaged and 10% overstaged. Both TRUS and MRI re-
sulted in improved accuracy in detecting the local extent of
cancer; 65% and 56% of cases were judged correctly by these
two modalities, but understaging occurred in 33% and 41%,
respectively.
With regard to TRUS, sensitivity in predicting capsular
extension ranges from 53% to 86%, with most reports favoring
the lower figures [37—40]. Similarly, specificity ranging between
70% and 94% has been reported, with most studies favoring the
lower figure. As I mentioned, CT scanning did not fare as well.
Sensitivity in detecting capsular penetration varied from 12% to
50% [37, 39, 41, 42]. Nor does MRI detect local extension as
well as TRUS does. Sensitivities of 29% to 54% have been
reported, although specificity is generally high (85% to 100%)
[37, 43, 44]. In summary, our current staging techniques bring
with them many false positives and false negatives.
These data might appear to present a dreary picture with
regard to accurate staging of prostatic cancer and the selection
of candidates for surgery. One of the most crucial variables in
this determination, however, is the presence or absence of
disease extension to the seminal vesicles. In this area, TRUS is
superior. For instance, Scardino and colleagues reported that
TRUS correctly identified seminal vesicle invasion in 82% of
patients [45]. This figure can be improved significantly by
TRUS-directed biopsy of the seminal vesicles [40].
Involvement of the pelvic lymph nodes is another important
criterion in selecting patients for surgery. In general, radio-
graphic techniques are not helpful in determining pelvic lymph
node involvement. Lymphangiography is of little value because
the obturator and hypogastric nodes that are often involved are
not commonly visualized with pedal lymphangiography tech-
niques. Thus, false-positive rates of 10% to 20% and false-
negative rates of 20% to 40% have been reported [36, 46].
Neither CT scanning nor MRI have been significantly more
successful in detecting pelvic lymph node metastases. These
studies can determine lymph node invasion in only approxi-
mately 50% of patients [47, 48]. Nevertheless, CT or MRI
typically is performed on the rationale that if very large nodes
are noted, percutaneous skinny-needle biopsy can be carried
out, thus avoiding formal surgical lymph node sampling [49].
Considerable enthusiasm has arisen recently for surgical lymph
node sampling by laparoscopic techniques, particularly in pa-
tients at high risk for pelvic lymph node spread [50].
In the United States, an alphabetical staging system is more
popular than is the International Union Contre Cancer (IUCC)
system of TNM (tumor stage; node status; distant inetastases)
in staging prostatic cancer. Variations of the Whitmore-Jewett
staging classifications have been in vogue for more than 15
years [35]. The one we employ at the College of Physicians and
Surgeons at Columbia University is consistent with the Whit-
more-Jewett system. Stages A and B comprise disease confined
to the prostate; stages C and D represent extraprostatic disease.
Stage A disease is defined as cancer that is inadvertently
found on biopsy after the obstructing portion of the prostate has
been removed for presumed benign enlargement. This staging is
further broken down into tumors thought to have little biologic
import (stage Al) versus tumors known to adversely affect the
patient's prognosis (stage A2) [35]. The distinction between
stages Al and A2 is based on both the volume of the tumor as
well as its histopathologic grade, and many different techniques
have been advocated for making this distinction [51, 52]. Most
pathologists would agree that small amounts of well-differenti-
ated cancer, less than 5% of the resected specimen, would be
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classified as stage Al. In all other conditions—either a small
amount of higher-grade malignancy or more diffusely evident,
well differentiated disease—the patient is labeled as having
stage A2 disease. All clinicians agree that stage A2 disease
confers a worse prognosis than does Al disease. Moreover, the
incidence of pelvic lymph node spread in stage A2 disease
(28%) is even higher than that for stage B disease (20%) [34].
Therefore patients with stage A2 prostatic carcinoma generally
are given additional therapy.
By definition, patients with stage Al disease have less risk of
tumor progression. However, the observation of disease pro-
gression within 10 years in approximately 20% of patients with
stage Al disease has fostered a more aggressive approach in
younger men (less than age 55) than was common in the past
[53, 54]. Other investigators continue to advise the traditional,
conservative approach of closely monitoring patients with stage
Al disease regardless of age [55]. Perhaps the application of
PSA density and rise of PSA over time will help determine the
most effective management of stage Al prostatic cancer. At
present, I favor monitoring patients with stage Al prostate
cancer unless they are less than 55 years old.
Stage B prostatic cancer indicates palpable disease confined
to the prostate. Stage B disease is variously subdivided numer-
ically to indicate the presence of a single nodule on one side of
the gland (B 1) versus involvement of an entire lobe (B2) or
bilateral tumor involvement (B3) [35]. The accuracy of deter-
mining tumor extent depends, of course, on histologic exami-
nation of excised tissue. Even with multiple preoperative biop-
sies, understaging can occur: bilateral cancer occurs in more
than 20% of men with presumably unilateral disease, and nearly
50% of patients with presumably organ-confined disease have
capsular penetration [56].
Most urologists believe that stage B disease requires aggres-
sive treatment, either radiation therapy or radical extirpation.
Some individuals adopt a laissez-faire approach to prostatic
cancer, citing the relatively low death rate from this disease in
the United States (32,000 cases annually), compared with the
number of new cases detected annually (122,000) [57]. If
screening identifies 5 million men in the United States as having
prostatic cancer, most of whom have incidental (stage Al)
disease, many individuals might receive treatment unnecessar-
ily. However, the most commonly employed screening tech-
niques, PSA and DRE, generally detect patients with more than
stage Al disease [21, 28].
Stage C prostatic carcinoma indicates local extension beyond
the prostatic gland, without distant metastases. Stage C patients
can be further subdivided to indicate individuals with simple
capsular penetration but negative histologic margins after rad-
ical prostatectomy, those who have positive margins at opera-
tion and, finally, those who have seminal vesicle involvement.
Nodal involvement is found in as many as 50% of these patients
[36].
Stage D indicates the presence of systemic metastases. Stage
D patients can be characterized as having Dl disease, involving
the pelvic lymph nodes only, or stage D2, indicating bony
metastases; when metastatic disease is present, it involves
these 2 sites 90% of the time. Finally, so-called stage DO
indicates patients with an elevated acid phosphatase level
despite the absence of imaging studies positive for metastases.
The determination of tumor grade in most malignancies
involves histologic assessment of tumor architecture and indi-
vidual cellular characteristics [58—60]. In the United States,
however, less attention is devoted to an analysis of individual
cellular characteristics such as size of nucleoli or nuclear
roundness, and more stock is placed in a classification schema
devised by Gleason 25 years ago [601. Gleason denotes five
separate architectural patterns but does not include individual
cellular grading in the classification. Each pattern has a numer-
ical grade (1 through 5), A primary and secondary pattern is
detected within each tumor, and the sum of the two patterns'
grades determines the "Gleason score" [2 through 10]. If only
a single pattern is seen within a lesion, its numerical grade is
doubled. The Gleason scoring system is popular because of its
high correlation with the incidence of metastatic disease and
patient survival [34, 61].
Two reports published in 1983 established a relationship
between the DNA content of the prostatic lesion and its grade
and stage [62, 63]. More recent work has shown a strong
relationship between tumor cell ploidy and survival in localized
as well as extensive disease [64, 65]. Virtually all studies show
a stepwise progression of worsening of tumor grade (and thus
prognosis) with deviations from normal (diploid) ploidy pat-
terns. Therefore, patients with tetraploid tumors fare worse
than do those with diploid lesions; aneuploid lesions seem to
foretell the worst outcome. Some investigators have utilized
DNA ploidy in the analysis of localized prostatic cancer, hoping
to find a correlation between surgical cure versus surgical
failure (defined by positive margins, pelvic lymphadenopathy,
or seminal vesicle invasion). Lee and colleagues found that
non-diploid lesions were positively correlated with seminal
vesicle involvement, and that both findings predicted incurabil-
ity by surgery [66]. Others, however, have shown no statisti-
cally significant relationship between ploidy and poor outcome;
in contrast, the Gleason score does correlate with surgical
incurability [67, 68].
Management
The therapies usually advocated for localized (stages A and
B) prostatic cancer are radical prostatectomy, external radio-
therapy, or brachytherapy, the interstitial implantation of ra-
dioactive material. The last approach is not applicable in
patients who have undergone TUR or open prostatectomy for
benign disease, as accurate radiation dosimetry is difficult to
achieve within the residual prostatic capsule. Therefore,
brachytherapy must be reserved for patients with stage B
disease and not attempted in patients with stage A prostatic
cancer. Despite decades of experience with these three treat-
ment alternatives, no consensus has yet been reached as to the
superiority of one versus another. In fact, the Uro-Oncology
Research Group has reported the only prospectively random-
ized, multi-institutional trial comparing radical prostatectomy
and external beam radiation therapy [70]. In this study, 98
patients with clinical stage A2 or stage B lesions underwent
routine staging studies (DRE, prostatic acid phosphate levels,
and bone scan) as well as surgical lymphadenectomy before
randomization into two treatment arms: 55 patients received
radiation therapy; 43 underwent radical prostatectomy. The
first evidence of treatment failure, such as elevation of prostatic
acid phosphatase, positive bone scan, or occurrence of distant
metastases, was used as an end point. Radical prostatectomy
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demonstrated statistically superior disease control compared
with radiation therapy. In response to this study, Bagshaw and
colleagues performed a retrospective analysis of similarly
staged patients treated at Stanford solely with external radiation
therapy [71]. The results of this study paralleled the outcome
with surgery in the Uro-Oncology Research Group study [70].
Was the initial impetus for radiation therapy to replace
radical prostatectomy a consequence of the morbidity ensuing
from the surgical approach? I suspect so. In the 1950s and
1960s, 5% to 15% of men undergoing radical prostatectomy
experienced some form of urinary incontinence; impotence
occurred in more than 90% of men undergoing surgical therapy
[72, 73]. As clinical experience with external radiation therapy
has increased, however, this approach proved to be not nearly
as innocuous as previously thought. Impotence occurred in 40%
to 50% of men receiving radiation therapy [71, 74]. Chronic
radiation cystitis occurred in 10% of those so treated, as did
chronic enteritis [71, 74—77].
More recently, radical prostatectomy again has attained
popularity as first-choice treatment for patients with localized
(stages A and B) prostatic cancer. This return of popularity is
related to two factors: the former morbidity of radical prosta-
tectomy has been remarkably reduced, and concerns about the
effectiveness of radiation therapy have increased. Major im-
provements in radical prostatectomy can be attributed to
Walsh, who first observed that sexual potency could be main-
tained postoperatively by the intraoperative preservation of the
cavernous nerves that course along the anterior rectal wall and
innervate the penis [77, 781. Overall, potency can be maintained
in 75% of men undergoing radical prostatectomy. The preser-
vation of penile erectility depends on the age of the patient and
the extent of the disease, but erectile capability has been
achieved in more than 90% of men under 60 with B I disease
only [79]. Walsh's modifications of the surgical approach to the
external sphincteric anatomy also decreased the incidence of
urinary incontinence after radical prostatectomy to as low as
2%. Further, his management of the dorsal vein complex has
greatly reduced the need for intraoperative blood transfusion.
Also, modern blood banking now allows patients to store 2 to 4
units of their own blood for autologous transfusion during
surgery.
Radical prostatectomy also has become popular again be-
cause of concerns about the effectiveness of radiation therapy
in managing localized prostatic cancer. Positive post-irradiation
biopsies of the prostate gland were reported in 35% to 92% of
patients between 1983 and 1987 [80—83]. Most studies have
shown that a positive biopsy predicts a statistically higher rate
of tumor progression and patient mortality [80, 82].
Brachytherapy has been utilized for prostatic cancer since
the early 1970s [69, 80, 82]. Brachytherapy with interstitial
iodine-125 has the advantage of carrying with it a decreased
incidence of impotence and injury to the bladder or rectum [69].
However, in my experience, post-therapy positive biopsy rates
in interstitially irradiated patients generally are higher than in
those undergoing external radiation therapy. This result sug-
gests difficulty in obtaining an even distribution of radiation
throughout the gland. In an attempt to improve isodose config-
uration, Ragde and coworkers developed a perineal template
for ultrasonically controlled insertion of radioactive seeds [84].
More recently, iridium-l92 implantation has been advocated
combined with external beam therapy. Donnelly et al achieved
a negative biopsy rate of 75% at 18 months [85]. However, the
morbidity of this therapy is prohibitive: significant proctitis,
cystitis, or both occurred in 18% of patients; 4% required
permanent colostomy; and 1% needed permanent urinary diver-
sion.
With all these conflicting data, how does the physician
appropriately counsel a patient with localized prostatic cancer?
Obviously, personal bias plays a role in such counsel. With that
said, let me present my views on the management of localized
prostatic cancer. The patient's age, state of health, and family
history are three important considerations in determining
whether to use surgical or radiation therapy. Calendar age alone
cannot be utilized to stratify patients for either treatment, but
greater than a 10-year life expectancy is required to justify
radical prostatectomy. An essential part of counseling the
patient is a consideration of the complete personal and family
medical history. For example, a 72-year-old man who is free of
cardiovascular, pulmonary, and diabetic disease and whose
parents both lived to their mid- to late 80s is a better candidate
for surgery than is a 62-year-old man who already has experi-
enced one heart attack, has active angina, and comes from a
family in which no male has lived beyond the age of 65.
Additional considerations in deciding on therapy are the
grade and stage of the malignancy. Surgical failure in patients
with high Gleason score cancers (8—10) is much more frequent
than in those with low (2—4) or intermediate (5—7) scores [67].
Similarly, positive margins, pelvic lymph node involvement,
and seminal vesicle extension occur more often in patients with
bulky disease versus local, nodular disease. Any patient who
has bulky disease and a high Gleason score should be counseled
against nerve-sparing radical prostatectomy; whether resec-
tions with wider excision should be utilized in these patients
remains to be determined, but I generally offer wide-excision
radical prostatectomy only when there is reasonable evidence
that the disease remains confined to the gland. When radical
prostatectomy is used in the patient with localized disease, the
decision regarding nerve-sparing or wider-excision approaches,
as I noted, depends both on the stage and grade of malignancy.
If nodular involvement is unilateral, the ipsilateral neurovascu-
lar bundle can be readily sacrificed. Because of the high
incidence of positive margins in patients with bilateral tumor
involvement, nerve-sparing prostatectomy should not be at-
tempted in these individuals [79]. Limited pelvic lymph node
dissection, sometimes using laparoscopic techniques, is per-
formed in all patients prior to radical prostatectomy. If the
pelvic nodes are involved (stage Dl), the radical prostatectomy
usually is abandoned.
What is suitable management for patients with stage A
disease? We treat patients with A2 disease precisely the same
as those with stage B illness. For patients with stage Al
prostatic carcinoma, we offer relatively young patients (less
than 55 years of age) definitive therapy in the form of radical
prostatectomy. After age 55, patients with stage Al disease are
subjected to TRUS with guided biopsies where indicated. If any
additional cancer is found, the patient is automatically upstaged
to stage A2 disease and again offered definitive therapy. In
contrast, if no additional foci are found, we monitor the patient
by serial rectal examination, TRUS, and PSA determination.
Let me emphasize that the objective of treatment of stage A
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and B prostatic cancer is absolute cure. Postoperative PSA
values should fall to the "female" range of less than 0.4 ng/ml
[21]. Indeed, prostatectomy series from the 1980s achieved this
goal: 15-year survival rates closely matched actuarial survival
curves for men of similar ages [86, 871. In patients treated with
radiation, recent evidence indicates that if PSA values do not
"normalize," that is, fall to 4.0 ng/ml within 6 to 12 months
after treatment, clinical progression is likely [88].
The traditional management of patients with stage C prostatic
cancer has been radiation therapy, which generally yields a 20%
15-year survival [60]. These depressing data can be partly
explained by the fact that more than 50% of these apparent
stage C patients have positive lymph nodes and thus actually
have stage Dl cancer [89]. It is generally agreed that radiation
therapy is by itself an ineffective treatment modality in stage Dl
patients [90]. Finally, there are a number of important compli-
cations of radiation therapy, including impotence (40% to 50%),
chronic cystitis (10%), and chronic enteritis (10%) [75, 76].
Over the past decade, a series of articles from the Mayo
Clinic has recounted an interesting, although non-randomized,
study of stage C and Dl prostatic cancer [65, 91, 92]. Initial
reports suggested that survival curves in patients with stage C
and Dl disease who were treated with radical hormonal pros-
tatectomy, pelvic lymph node dissection, and adjunctive hor-
monal therapy were identical to actuarial survival curves for
men of similar ages [91]. In an update 5 years later, stage C
patients undergoing hormonal therapy at the time of prostatec-
tomy had a 10-year survival rate of 67% [92]. A more recent
analysis has stratified patients according to DNA ploidy status
[65]. If a patient with stage C or Dl cancer has a diploid lesion,
the aggressive surgical approach along with early hormonal
therapy results in survivals that appear longer than actuarial
expectation. These interesting data have not been derived from
a prospective randomized study, however. Such a study is
currently gathering patients under the auspices of the South-
west Oncology Group (Benson MC, personal communication).
A similar experience in stage Dl patients undergoing radical
prostatectomy and early endocrine therapy was reported by
deKernion at UCLA, however [93], These data are especially
encouraging in view of the poor experience with radiation
therapy in patients with stage C prostatic cancer, in whom
5-year survival rates average 60% to 65%, and 10-year survival
approximates 35% [94]. Similarly, the combined approach of
prostatectomy with hormonal therapy is appealing when com-
pared with the mean survival rate of 6 years in stageD! patients
treated with any other modality [951.
Because these data offer renewed hope in managing patients
with stage C and Dl disease, I currently offer the so-called
"Mayo approach" to younger men (under age 55) with stage C
and Dl prostatic cancer. In an attempt to discern which patients
would benefit from a combination of surgery and hormonal
therapy, we have analyzed ploidy status on the needle biopsy
specimens prior to offering this treatment. If aneuploidy or
tetraploidy is found, the patient is not considered a candidate. If
a diploid tumor is confirmed, we offer the therapy, although we
inform the patient that the treatment is not yet clinically proven.
How does one best manage the patient who has metastatic
prostatic carcinoma? Although not tumorigenic, testosterone is
essential to the perpetuation of prostatic cancer [96]. The
source of the vast majority of the androgenic substances that
support prostatic cancer is the testes; approximately 5% of
circulating androgens derive from the adrenal secretion of
androstenedione and dehydroepiandrosterone.
Androgenic support is essential to the prostatic cancer cell,
so altering its hormonal milieu remains the mainstay of treat-
ment of metastatic prostate cancer. The "gold standard"
against which other treatments must be compared is bilateral
orchiectomy. Orchiectomy is a simple surgical procedure that
can be carried out on an ambulatory basis under local anesthe-
sia. It lowers the plasma testosterone to castrate levels depend-
ably. This single treatment evokes a salutary response in 80% of
patients; the mean duration of effectiveness averages 2.5 years
[97]. Estrogen therapy, utilizing diethylstilbestrol at a dosage
level of 5 mg daily, produces significant cardiovascular morbid-
ity [98]. But when dosage levels are reduced to 1 mg daily, to
avoid cardiovascular complications, plasma testosterone does
not fall to levels seen in orchiectomized patients [99]. Even
when 3 mg daily is employed to ensure very low levels of
plasma testosterone, significant cardiovascular complications
occur [100]. Therefore, unless one has compelling reasons to
use it, estrogen therapy should be avoided in patients with
metastatic prostatic cancer.
More recently, analogues of luteinizing-hormone-releasing
hormone (LHRH) have been advocated for the treatment of
metastatic prostatic cancer. These agents achieve their effect by
down-regulating pituitary receptors for LHRH after initially
stimulating its release [100, 101]. The most common side effect
of LHRH analogue therapy is hot flashes [100]. Other draw-
backs include the mode of administration (injection or nasal
insufflation) [100, 101]. The most important side effect of LHRH
analogue therapy is the induction of a flare of disease progres-
sion during the initial treatment period, when the plasma
testosterone level rises. If utilized as monotherapy, LHRH
analogue treatment is contraindicated in patients with impend-
ing spinal cord compression or bilateral ureteral obstruction
caused by tumor [100]. Pre-treatment of the patient with an
anti-androgen, however, can avert the effects of the so-called
"flare phenomenon" [1011. A distinct disadvantage of LHRH
analogue therapy is its cost. At present, two commercially
available agents are approved for use in the United States; the
retail cost of these agents is close to $5000 annually.
When counseling a patient with metastatic prostatic cancer
who is to undergo either treatment with an LHRH analogue or
bilateral orchiectomy, one should explain the likely effects on
sexual function. Both treatments are accompanied by a de-
crease in erectile capability as well as reduced libido.
Some attention has been directed toward adrenal manipula-
tion in the surgically or medically castrated patient. Labrie et al
addressed the issue of androgen-induced stimulation of the
adrenals and reported much improved response and survival
rates in patients treated with a combination of an LHRH
analogue and an anti-androgen [102]. This report initially was
received with considerable skepticism throughout the world, as
Labrie's initial study relied on historic controls. A number of
international studies have since been initiated to examine the
impact of total androgen ablation in the treatment of metastatic
prostatic cancer.
In the United States, a multicenter randomized trial showed
a 7-month survival advantage in patients treated with an LHRH
analogue along with the anti-androgen flutamide, compared
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with LHRH analogue alone [1031. Similarly, a Canadian trial
comparing orchiectomy versus orchiectomy plus the anti-an-
drogen nilutamide showed a significant survival advantage (3.5
months, somewhat shorter than in the LHRH study) for the
patients receiving combination therapy [104]. As patients have
been followed longer, however, the statistical significance of
the survival advantage has disappeared (Trachtenberg J, per-
sonal communication).
The controversy of total androgen ablation versus testicular
ablation alone continues, as contradictory results are reported
from various groups throughout the world. The European
Oncology and Radiation Therapy Committee (EORTC) recently
reported on 367 patients in whom total adrenal ablation con-
ferred no statistically significant advantage [1051. Similarly, a
British study in 525 men showed no advantage for total andro-
gen ablation [106]. An international, randomized, double-
blinded study of 457 patients did show a statistically significant
improvement in the survival rate in men treated with orchiec-
tomy plus the anti-androgen nilutamide as compared with men
treated with orchiectomy plus placebo [107].
In summary, the data are conflicting with regard to the value
of total androgen ablation in the management of metastatic
prostatic cancer. Even so, the trend in the United States is to
offer an LHRH analogue plus flutamide in the majority of
individuals facing a treatment decision. One consideration that
must be addressed is the total cost of hormone therapy: an
annual expenditure of $7500 per patient is required.
Finally, the efficacy of chemotherapy for prostatic cancer has
remained unclear. Randomized and controlled studies under the
aegis of the NIH's National Prostatic Cancer Project (NPCP)
have disclosed only minor treatment advantages (measured in
weeks only) with single-agent chemotherapy. In an excellent
review of the NPCP and other experiences, Eisenberger and
Abrams showed only minor advantages from chemotherapy in
prostatic cancer, whether single-agent or multi-agent strategies
were employed [108]. Attention has since been directed to
growth factor inhibitors in the management of hormone-resis-
tant prostatic cancer. Suramin, an antihelminthic agent, was
studied in a National Cancer Institute phase-2 trial of 38
patients with hormone-refractory disease [109]. Suramin pro-
duced a 55% response rate but a median time to progression of
disease of only 26 weeks. At present, valid chemotherapeutic
management of metastatic prostatic cancer has not been de-
scribed. Patients should be entered into formal clinical trials.
Questions and answers
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): You stated that
the incidence of prostate cancer at autopsy seems to be the
same worldwide, yet the incidence of clinically overt cancer of
the prostate varies widely. You also commented that the ras
gene might be important in the pathogenesis of this disease. Has
anyone looked at the prevalence of the ras or other genes to see
whether a genetic difference might underlie the clinical differ-
ence?
DR. OLssoN: Approximately 0.6% or 0.7% of the National
Cancer Institute (NC!) budget is spent on prostatic cancer
research. Although that small amount should increase this year,
money has not been available for those studies. An NC!
conference in April 1991 identified crucial areas for prostatic
cancer investigation. It would be fair to say that the most
important area identified was the need to distinguish between
the incidental prostatic cancer that is a pathologic oddity at
autopsy and the clinical cancers that require treatment. These
important studies have not yet been done.
DR. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Is the
level of PSA affected by acute or chronic prostatitis? Also, does
digital rectal examination elevate the PSA?
DR. OLssoN: It is; prostatitis certainly raises the PSA signif-
icantly. I have seen levels upwards of 25 in patients with
normal-sized glands who had active prostatitis. Initially, digital
rectal examination was thought to cause an elevated PSA. The
customary teaching was that the PSA should be drawn before a
DRE is carried out. But in the Prostate Cancer Awareness
Week studies, in which PSAs were drawn both before and after
DRE in more than 1600 men, routine DRE caused no statisti-
cally significant increase in PSA [1101.
DR. MADIAs: Obviously PSA is an objective test, whereas
digital examination is subjective. Has examiner variability been
tested in digital examination of the prostate?
DR. OLssoN: Tremendous variability exists in DRE findings
within one examiner and from examiner to examiner. Usually,
although not always, urologists detect abnormalities better than
do internists, but some very good internists can detect subtle
changes. Every urologist has seen men with obviously abnor-
mal prostates whose lesions have not been detected even
though these men visit their internists.
DR. MADIAS: Has this variability among practitioners been
tested formally?
DR. OLssoN: No, that issue has not been tested.
DR. MADIAS: Could you address the utility of PSA in the
followup of patients who have prostatic cancer?
DR. OLssoN: The main advantage of PSA is its application in
patients who have had radical prostatectomy. Patients post
radical prostatectomy should not have a detectable PSA level.
It is an all-or-none phenomenon. If one has no prostatic tissue,
one has no reason to have a detectable level. If one does have
a detectable level, it usually means therapy has failed or will do
so. Occasionally, it reflects the fact that a fragment of the
normal prostate gland has been left. Moreover, recent data
published by Russell suggest that radiation therapy patients
who don't achieve a normal PSA level (<4.0 ng!ml) do not do
well [88]. Again, I suspect that in these patients who have not
had surgery, the benign portion of the remaining prostate
contributes to the elevated serum PSA level.
DR. HARRINGTON: How well does the PSA level correlate
with the staging system?
DR. OLssoN: It is reasonably volume sensitive. The greater
the tumor volume, the higher the PSA. That is why PSAD is a
valuable concept not only for the diagnosis but also for the
projection of incurability. There is a problem with higher
degrees of tumor dedifferentiation; the amount of PSA pro-
duced per gram of cancer tissue drops with increasing dediffer-
entiation.
DR. HARRINGTON: Could either PSA or PSAD substitute for
the classic staging system?
DR. OLssoN: It clearly does to some extent. But the classic
staging paramenters should be utilized with the PSA or PSAD
determination in a complementary fashion. However, the PSA
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determination has remarkably reduced, for example, the need
for followup scintillation scans of the bone. It is rare to have a
positive bone scan when the PSA is less than 10 ng/ml. Also, in
the followup and monitoring of the patient with prostatic
cancer, PSA has largely done away with acid phosphatase
determinations. With the exception of the occasional patient
whose tumor stops producing PSA, you have an almost fool-
proof, easy technique for monitoring the patient with prostatic
cancer.
DR. HARRINGTON: Does a relationship exist between normal
plasma testosterone and PSA values?
Da. OLssoN: I do know that PSA is androgen dependent, but
whether there is a relationship between plasma testosterone and
PSA, I don't know.
Da. JEANINE CARLSON (Division of Nephrology, New En-
gland Medical Center): You mentioned that if the PSAD is
greater than 0.8 ng/ml/cc, the cancer is not resectable. Is that
because the lesion is metastatic?
DR. OLssoN: It probably is, although we don't have enough
data on this point yet. We have expanded our original study
from 37 to more than 100 patients. If the PSAD is higher than
0.6 nglml/cc, the likelihood of surgical cure is no better than
25% of cases. These all were patients with presumed stage B
disease who, in retrospect, were found to have positive nodes
(stage Dl) or positive margins or seminal vesicals (stage C).
DR. RONALD D. PERRONE (Division of Nephroiogy, New
England Medical Center): Has anyone looked at the expression
of PSA at the cellular level, that is, using in-situ hybridization or
histochemistry as a prognostic factor?
DR. OLssoN: To some extent, there is a greater variability of
PSA expression in the cell in the higher grades of prostatic
cancer. I suppose that variability could be used as prognostic
information. The direct answer to your question, however, is
no.
DR. GRANNUM SANT (Associate Urologist-in-Chief, New
England Medical Center): Like you and everybody else, we are
doing more radical prostatectomies, but it seems that about 30%
to 40% of our patients, in spite of negative pre-operative
staging, have positive margins and/or microscopic involvement
of the seminal vesicles. How do you approach similar patients
in your practice?
DR. OLssoN: Again, we use the PSA level and PSAD to try to
separate out patients who are at high risk. In these patients I
will likely repeat a TRUS and obtain specific biopsy samples
from the seminal vesicles. Alternatively, I might have the
patient undergo MRI with a trans-rectal coil to further analyze
the prostate capsule and seminal vesicles. There is a great deal
of variability throughout the country in the judgment of which
patients are candidates for radical prostatectomy. For example,
in Walsh's data, the preponderance of cases are well-selected
patients with B I cancers [77, 78]. The Catalona data showed a
preponderance of B2 patients, so you can easily understand the
high positive margin rate he reports [56] compared with the data
from Walsh. I am afraid that urologists in the community evince
too much enthusiasm for surgery. The more likely you are to be
overly enthusiastic for radical prostatectomy, the more treat-
ment failures you are going to have.
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): What is the principle by which PSA
distinguishes latent from clinically significant prostatic carci-
noma?
DR. OLssoN: It doesn't. The studies that Stamey has done
have shown the volumetric relationship between prostatic can-
cer and PSA levels [21]. However, one would have to assume
latent cancers to be so small that their contribution to a serum
PSA level would be masked by the amount of PSA resulting
from the predictable benign prostatic hypertrophy in these men.
DR. MADLAS: What do we know about the natural history of
latent prostatic cancer?
DR. OLssoN: Really, we know remarkably little, because the
determination of latent cancer is usually made at autopsy. The
best clinical counterpart to latent prostatic cancer is stage Al
disease, in which some studies indicate a slow tendency to
progression (15% over 8 to 10 years) [53].
DR. LEVEY: Given the effect of androgens on the growth of
prostatic carcinoma, what is the rationale for not including
anti-androgens or hormonal therapy for earlier stages of the
disease?
DR. OLssoN: The rationale dates back to the Veterans
Administration Cooperative Urology Research Group
(VACURG) trials which showed that delayed endocrine manip-
ulation resulted in no shorter survival than did earlier interven-
tion with endocrine therapy. The concept is that most prostatic
cancers already have a degree of heterogeneity in their tumor
cell population, with the result that some of the cells are
endocrine sensitive and others are endocrine resistant. As soon
as you reduce the androgen-sensitive cells to a stem cell
population, the resistant cells continue to divide without com-
petition from the sensitive cells for blood supply, nutrients, and
the like. If you were to use hormonal treatment for localized
prostatic cancer (as an alternative to surgery or radiation), you
would likely favor the growth of a subset of cells that are
endocrine resistant. These cells would be certain to then
progress and metastasize.
DR. LEVEY: Has endocrine manipulation been tried as adju-
vant therapy in a postoperative fashion?
DR. OLssoN: Yes. For example, the stage C and Dl data I
reviewed from the Mayo Clinic were used to study this point
[65, 91, 92]. This group observed that combined therapy of this
nature was beneficial in high-stage tumors that were diploid on
flow cytometric DNA analysis. Endocrine therapy had no effect
on the tetraploid or aneuploid tumor patients, however [92].
Another issue involving adjuvant therapy is neo-adjuvant en-
docrine manipulation, which has gained attention recently.
Neo-adjuvant therapy attempts to down-size the tumor before
surgical excision. This approach has been studied for decades,
and no conclusions have been reached. There is no question
that you can down-size tumors, but whether survival can be
prolonged remains questionable. For example, it would be
unlikely that, as endocrine-sensitive cells regress with hor-
monal manipulation, their residual stem cells all will be within
the prostate capsule and surgically removed. One must recall
that the first article on neo-adjuvant hormone therapy before
radical prostatectomy was published in 1945 [111]. If this
technique had definitive value it would have been apparent by
now.
DR. BRIAN PEREIRA (Division of Nephrology, New England
Medical Center): You mentioned that patterns in the epidemi-
ology in some populations, like the Japanese, are changing, and
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you attributed that change to Westernization. Is it possible that
the increased longevity of these peoples has increased the
prevalence of prostatic cancer?
DR. OLssoN: No. That is not the pertinent observation,
because even though there may be some longevity prolongation
both in Japan and the United States, the characteristic differ-
ences are still remarkable. Furthermore, when men in China are
studied, the incidence of clinical cancer remains low. This
finding, I believe, reflects the reluctance of the Chinese to
become Westernized. Finally, changes in longevity do not
explain the increasing incidence of prostatic cancer in the
Japanese male who has immigrated to the United States.
DR. PEREIRA: Do sexual practices affect the incidence of
prostatic cancer?
DR. OLssoN: Many articles over decades have suggested a
putative relationship between venereal disease and prostatic
cancer [1121; others have denied any such relationship [1131.
DR. AJAY SINGH (Division of Nephrology, New England
Medical Center): You stated in your talk that the number of
patients who undergo radical prostatectomy each year in the
United States has steadily increased. Does this increase reflect
better detection of clinically significant prostatic cancers? Or
are urologists removing all prostatic cancers, clinically signifi-
cant or not, in the hope of avoiding any uncertainty about the
ultimate outcome?
DR. OLssoN: I don't know to what extent the surgery is
influenced by either of those factors. I don't think that there is
too much treatment of the clinically insignificant cancer yet. If
physicians respond to trip points of PSA from anywhere from 4
to 10 ng/ml, I don't think they will detect many latent or
incidental cancers. There is no question that the driving force
for PSA screening is the American male himself. If his internist
does not offer him PSA, he will say that he read about the test
in Reader's Digest, the Wall Street Journal, or the New York
Times, and that he wants this test. Look at 1987, for example.
There were 90,000 new cases of prostatic cancer in the United
States; by 1989 the number had exceeded 100,000. In 1991 there
were 122,000. I think we'll see 200,000 by 1995, just because of
the American public's desire to be screened.
DR. LEVEY: Are the PSA levels influenced at all by renal
insufficiency?
DR. OLssoN: I don't know. The only aberration we have
found in this assay is a recent observation made by one of my
house staff, who had a patient with a very high PSA elevation
that was evanescent. Followup PSA determinations and DRE
all were normal. On further inquiry, the house officer found that
the man had had a fluorescein test for his eyes just before the
initial PSA was drawn. It turns out that the fluorescent assay for
PSA is interfered with by the fluorescein absorbed after the eye
test.
Reprint requests to Dr. C. Olsson, Chairman, Department of Urol-
ogy, Columbia-Presbyterian Medical Center, The Allen Pavill ion, 5141
Broadway, Room 3-005, New York, New York 10034, USA
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